- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05125809
Studie for å vurdere dose, effekt og sikkerhet av Setrusumab hos deltakere med Osteogenesis Imperfecta (Orbit)
En operasjonelt sømløs, randomisert fase 2/3-studie bestående av en fase 2 enkeltblind, doseevalueringsfase og en fase 3 dobbeltblind, placebokontrollert fase for å vurdere effekten og sikkerheten til Setrusumab hos pasienter med osteogenesis imperfecta
The primary objectives of the study are to identify a setrusumab dosing strategy in participants with OI and to evaluate the effect of setrusumab vs placebo on reduction in fracture rate.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Participants in Phase 2 will be randomized 1:1 to receive low dose or high dose setrusumab. Phase 2 participants will continue receiving their assigned dose of setrusumab until all Phase 2 participants have completed the Month 6 study visit. After this point, Phase 2 participants will begin receiving the selected dosing strategy in the Phase 2 open-label Treatment Extension Period. Phase 3 participants will be randomized 2:1 to receive setrusumab or placebo during the double-blind treatment period. Phase 3 participants will transition to the open-label Treatment Extension Period after the end of the double-blind period. Participants in the Phase 2 and Phase 3 treatment extension periods will receive open-label setrusumab treatment for at least 12 months, and have the option to remain in the open-label treatment period until setrusumab is commercially available in their region. An optional substudy will be conducted in approximately 10 participants (≥ 8 years) consisting of a bone biopsy to investigate the impact of setrusumab on bone histomorphology.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Melbourne, Australia
- Royal Children's Hospital
-
-
Queensland
-
South Brisbane, Queensland, Australia, QLD 4101
- Queensland Paediatric Endocrinology
-
-
-
-
-
Montreal, Canada, H4A 3J1
- McGill University Health Centre
-
Toronto, Canada
- University of Toronto- The Hospital for Sick Children (SickKids)
-
-
Ontario
-
London, Ontario, Canada
- London Health Sciences Center
-
Ottawa, Ontario, Canada, K1H 8L1
- Children's Hospital of Eastern Ontario
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72202
- Arkansas Children's Hospital
-
-
California
-
Los Angeles, California, Forente stater, 90027
- Children's Hospital Los Angeles
-
Sacramento, California, Forente stater, 95817
- Shriners Hospital for Children - Northern California
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Children's Hospital Colorado
-
-
Connecticut
-
Hartford, Connecticut, Forente stater, 06106
- Connecticut Children's Medical Center
-
New Haven, Connecticut, Forente stater, 06510
- Yale New Haven Hospital
-
-
Delaware
-
Wilmington, Delaware, Forente stater, 19803
- Nemours/ Alfred i. duPoint Hospital for Children
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20010
- Children's National Medical Center
-
-
Florida
-
Tampa, Florida, Forente stater, 33612
- University of South Florida
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60707
- Shriners Hospitals for Children - Chicago
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Indiana University Hospital
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21205
- Kennedy Krieger Institute
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63110
- Washington University School of Medicine
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68114
- Children's Hospital and Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87106
- New Mexico Clinical Research & Osteoporosis Center, Inc.
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater, 28203
- Atrium Health Levine Children's Hospital
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43205
- Nationwide Children's Hospital- Ohio State University College of Medicine
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- The Children's Hospital of Philadelphia
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Fort Worth, Texas, Forente stater, 76104
- Cook Children's Medical Center
-
Houston, Texas, Forente stater, 77030
- Baylor College of Medicine
-
-
Wisconsin
-
Madison, Wisconsin, Forente stater, 53792
- UW Health University Hospital
-
-
-
-
-
Paris, Frankrike
- Institut Imagine
-
-
-
-
-
Bologna, Italia
- Istituto Ortopedico Rizzoli
-
Rome, Italia, 00161
- Azienda Ospedaliera Universitaria Policlinico Umberto I
-
Verona, Italia
- Universita Degli Studi Di Verona
-
-
-
-
-
Utrecht, Nederland
- Wilhelmina Children's Hospital
-
-
-
-
-
Lodz, Polen
- Uniwersytet Medyczny w Lodzi - Klinika Endokrynologii i Chorob Metabolicznych
-
-
-
-
-
Lisbon, Portugal, 1649-028
- Hospital de Santa Maria
-
Porto, Portugal, 4099-001
- Centro Hospitalar do Porto
-
-
-
-
-
Manchester, Storbritannia
- Royal Manchester Childrens Hospital
-
Sheffield, Storbritannia, S10 2TH
- Sheffield Children's NHS Foundation Trust
-
-
-
-
-
Ankara, Tyrkia (Türkiye)
- Gazi University
-
Istanbul, Tyrkia (Türkiye)
- Marmara University
-
-
-
-
-
Cologne, Tyskland
- University of Cologne
-
Magdeburg, Tyskland, 39106
- Otto von Guericke University Magdeburg
-
Würzburg, Tyskland, 97074
- Musculoskeletal Center Würzburg
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Diagnosis of OI Type I, III, or IV as confirmed by identification of pathogenic or likely pathogenic genetic variants in COL1A1 or COL1A2. If a variant of uncertain significance is identified, then clinical presence of the expected phenotype can be used to confirm the diagnosis
- ≥ 1 fracture in the past 12 months, ≥ 2 fractures in the past 24 months or ≥ 1 tibia, femur or humerus fracture in the past 24 months
- Serum 25-hydroxyvitamin D ≥ 20 ng/mL at the Screening Visit. If 25-hydroxyvitamin D levels are below 20 ng/mL, 25-hydroxyvitamin D testing can repeated after a minimum of 14 days of vitamin D supplementation as directed by the treating physician
- Willing to not receive bisphosphonate therapy during the study
- From the period following informed consent to 60 days after the last dose of the study drug, females of childbearing potential and fertile males must consent to use highly effective contraception. If female, agree not to become pregnant. If male, agree not to father a child or donate sperm
- Willing and able to provide informed consent for subjects greater than or equal to 18 years of age, or provide assent (if possible) and have a legally authorized representative provide informed consent, after the nature of the study has been explained and prior to any research-related procedures
- Willing to provide access to medical records for the collection of radiographic data, fracture data, growth data, and disease history
- Must, in the opinion of the Investigator, be willing and able to complete all aspects of the study, adhere to the study visit schedule, and comply with the assessments
Exclusion Criteria:
-
History of skeletal malignancies or bone metastases at any time
-
History of neural foraminal stenosis (except if due to scoliosis)
-
Clinical manifestations of Chiari malformation or basilar invagination. Presence of any other neurologic disease that has been unstable within past 2 years requires review by the Medical Monitor
-
History of or uncontrolled concomitant diseases such as hypo/hyperparathyroidism, Paget's disease, abnormal thyroid function, thyroid disease or other endocrine disorders or conditions that could affect bone metabolism such as Stage IV/V renal disease
-
Rickets or any skeletal condition (other than OI) leading to long-bone deformities and/or increased risk of fractures
-
History of stroke, myocardial infarction, transient ischemic attack or angina.
-
Hypocalcemia, defined as serum calcium levels below the age-adjusted normal limits after a ≥ 4 hour fast
-
Estimated glomerular filtration rate ≤ 29 mL/min/1.73 m2
-
Prior treatment with the following:
- Teriparatide, growth hormone, bone anabolic, or anti-resorptive medications (other than bisphosphonates) within 6 months of the first dose with study drug (Month 0)
- Denosumab within 24 months of Screening
- Romosozumab at any time
-
Documented alcohol and/or drug abuse within 12 months prior to dosing or evidence of such abuse as indicated by the laboratory results during the Screening assessments
-
Presence or history of any condition that, in the view of the Investigator, would interfere with participation, pose undue risk, or would confound interpretation of results
-
Known hypersensitivity to setrusumab or excipients that, in the judgment of the Investigator, places the subject at increased risk for adverse effects
-
History of external radiation therapy
-
Pregnant or breastfeeding or planning to become pregnant (self or partner) at any time during the study
-
Use of any investigational product or investigational medical device within 4 weeks or 5 half-lives of investigational drug (whichever is longer) prior to Screening, or during the study (per discretion of the Investigator in consultation with the Medical Monitor)
-
Concurrent participation in another clinical study without prior approval from the Investigator in consultation with the Medical Monitor
-
For Phase 2 Only: A history of bone surgery within the previous 6 months prior to Screening or planned bone surgery for the first 3 months of the study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Low Dose Setrusumab -> Open-Label (OL) Setrusumab Selected Dose
Single-blind setrusumab low dose during Phase 2 followed by open-label setrusumab selected dose During treatment and treatment extension periods, participants may receive supplementation with calcium and vitamin D to maintain normal values as directed by the treating physician |
A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
Andre navn:
|
|
Eksperimentell: High Dose Setrusumab -> OL Setrusumab Selected Dose
Single-blind setrusumab high dose during Phase 2 followed by open-label setrusumab During treatment and treatment extension periods, participants may receive supplementation with calcium and vitamin D to maintain normal values as directed by the treating physician |
A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
Andre navn:
|
|
Eksperimentell: Setrusumab Selected Dose -> OL Setrusumab Selected Dose
Double-blind setrusumab selected dose during Phase 3 followed by open-label setrusumab During treatment and treatment extension periods, participants may receive supplementation with calcium and vitamin D to maintain normal values as directed by the treating physician |
A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
Andre navn:
|
|
Placebo komparator: Placebo -> OL Setrusumab Selected Dose
Double-blind placebo during Phase 3 followed by open-label setrusumab During treatment and treatment extension periods, participants may receive supplementation with calcium and vitamin D to maintain normal values as directed by the treating physician |
A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
Andre navn:
A 5% dextrose/glucose solution administered QM via IV infusion |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Fase 2: Prosentvis endring i serumaminoterminalt propeptid av type 1 prokollagen (P1NP) fra baseline ved måned 1
Tidsramme: Grunnlinje, måned 1
|
Grunnlinje, måned 1
|
|
Fase 3: Årsatt hastighet for alle radiografisk bekreftede brudd, unntatt morfometriske vertebrale brudd og brudd i fingrene, tærne, ansiktet og hodeskallen ved den primære analysen
Tidsramme: Opp til måned 24
|
Opp til måned 24
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Fase 2: Serum Setrusumab Konsentrasjon
Tidsramme: Fra forhåndsdosering til måned 24
|
Fra forhåndsdosering til måned 24
|
|
Fase 2: Baseline-korrigert område under effektkurven (AUEC) for serum P1NP over en 1 og 2-måneders periode
Tidsramme: Grunnlinje, opptil måned 2
|
Grunnlinje, opptil måned 2
|
|
Fase 2: Prosentvis endring fra baseline over tid i beinomsetningsmarkør: P1NP
Tidsramme: Grunnlinje, opptil måned 24
|
Grunnlinje, opptil måned 24
|
|
Fase 2: Prosentvis endring fra baseline over tid i beinomsetningsmarkør: Osteokalsin (OCN)
Tidsramme: Grunnlinje, opptil måned 24
|
Grunnlinje, opptil måned 24
|
|
Fase 2: Endring fra baseline i Dual Energy X-ray (DXA) Lumbal Spine Bone Mineral Density (BMD) Z-score over tid
Tidsramme: Grunnlinje, opptil måned 24
|
Grunnlinje, opptil måned 24
|
|
Fase 2: Prosentvis endring fra baseline i DXA Lumbal Spine BMD over tid
Tidsramme: Grunnlinje, opptil måned 24
|
Grunnlinje, opptil måned 24
|
|
Fase 2: Antall deltakere med behandling Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) og Adverse Events of Special Interest (AESIs)
Tidsramme: Opp til måned 24
|
Opp til måned 24
|
|
Fase 3: Antall deltakere med behandling Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) og Adverse Events of Special Interest (AESIs)
Tidsramme: Opp til måned 24
|
Opp til måned 24
|
|
Fase 2: Antall deltakere med anti-Setrusumab bindende og nøytraliserende antistoffer
Tidsramme: Opp til måned 24
|
Opp til måned 24
|
|
Fase 3: Antall deltakere med anti-Setrusumab bindende og nøytraliserende antistoffer
Tidsramme: Opp til måned 24
|
Opp til måned 24
|
|
Fase 3: Årlig hastighet for alle radiografisk bekreftede brudd, unntatt morfometriske vertebrale brudd, men inkludert brudd på fingrene, tærne, ansiktet og hodeskallen ved den primære analysen
Tidsramme: Opp til måned 24
|
Opp til måned 24
|
|
Fase 3: Årsatt hastighet for alle radiografisk bekreftede brudd ved primæranalysen
Tidsramme: Opp til måned 24
|
Opp til måned 24
|
|
Fase 3: Endring fra baseline i DXA lumbal ryggrad BMD Z-score ved primæranalysen
Tidsramme: Baseline, opp til måned 24
|
Baseline, opp til måned 24
|
|
Fase 3: Endring fra baseline i pediatrisk ortopedisk samfunn i Nord-Amerika Pediatriske utfall Datainnsamlingsinstrument (Posna-PODCI) Sport/fysisk fungerende subscale score for pediatriske deltakere ved primæranalysen
Tidsramme: Baseline, opp til måned 24
|
Baseline, opp til måned 24
|
|
Fase 3: Andel deltakere som opplever nye radiografisk bekreftede brudd, unntatt morfometriske vertebrale brudd og brudd i fingrene, tærne, ansiktet og hodeskallen ved den primære analysen
Tidsramme: Opp til måned 24
|
Opp til måned 24
|
|
Fase 3: Endring fra baseline i Posna-PODCI Pain/Comfort Subscale Score for pediatriske deltakere ved primæranalysen
Tidsramme: Baseline, opp til måned 24
|
Baseline, opp til måned 24
|
|
Fase 3: Endring fra baseline i 36-elements kortform Health Survey (SF-36) Fysisk fungerende domeneskala for voksne deltakere ved primæranalysen
Tidsramme: Baseline, opp til måned 24
|
Baseline, opp til måned 24
|
|
Fase 3: Endring fra baseline i SF-36 Bodily Pain (BP) domeneskala for voksne deltakere ved primæranalysen
Tidsramme: Baseline, opp til måned 24
|
Baseline, opp til måned 24
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studieleder: Ultragenyx Medical Director, Ultragenyx Pharmaceutical Inc
Publikasjoner og nyttige lenker
Generelle publikasjoner
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- UX143-CL301
- 2021-006597-23 (EudraCT-nummer)
- 2024-510919-29-00 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .